How does the selective small-molecule AHR inhibitor BAY affect gemcitabine response in pancreatic cancer cells?
Label:chem
Topic
Gemcitabine is a nucleoside analogue used to treat pancreatic cancer, but its efficacy is often limited by chemoresistance. The AHR inhibitor BAY has been shown to modulate the expression of genes involved in gemcitabine metabolism and response.
Answer
BAY increases the effectiveness of gemcitabine by enhancing the expression of DCK and promoting the translocation of ELAVL1 from the nucleus to the cytoplasm, where it stabilizes DCK mRNA. This results in increased DCK protein levels and improved gemcitabine activation, leading to enhanced treatment efficacy. In cell viability assays, BAY treatment prior to gemcitabine significantly reduced cell viability and colony formation compared to gemcitabine alone.
Return to Home
Chemical List
Knowledge you may be interested in